Parathyroid hormone is under clinical development by Takeda Pharmaceutical and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Parathyroid hormone’s likelihood of approval (LoA) and phase transition for Post Menopausal Osteoporosis took place on 16 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Parathyroid hormone Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Parathyroid hormone overview

Parathyroid hormone (Preotact / Preotakt / Natpara / SHP-634 / TAK-834 / Natpar) is produced in Escherichia coli by recombinant DNA technology. It is formulated as powder for solution for injection for subcutaneous route of administration. It is indicated for the treatment of osteoporosis (a disease that makes bones fragile) in postmenopausal women who are at high risk of fractures. Parathyroid Hormone (SHP-634/Natpar) indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

It was under development for hypothyroidism in Japan. It was also under development for the treatment of postmenopausal women with osteoporosis in the U.S.

Takeda Pharmaceutical overview

Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

Quick View Parathyroid hormone LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Parathyroid hormone
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Hormonal Disorders
  • Musculoskeletal Disorders
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.